Systemic review and network meta-analysis: Prophylactic antibiotic therapy for spontaneous bacterial peritonitis

Figure 1 Flow chart of assessment of studies identified in the network meta-analysis.

Figure 2 Network meta-analysis of studies assessing the risk of spontaneous bacterial peritonitis. A: Network of treatment comparisons between antibiotics. Numbers indicate the number of studies comparing the two connected treatment arms; B: Relative effects of between each treatment. The numbers in the cell represent the odds ratio (95%CI) of the column defining modality relative to the row defining treatment; C: Rank probability (consistency model) for each antibiotic. Indicated is the possibility of each rank (No. 5 is the best). The overall rank interpreted by surface under the cumulative ranking technique is shown in the table. surface under the cumulative rankings in the table are reordered in the conventional ascending sequence. CPFX: Ciprofloxacin; NFX: Norfloxacin; RFX: Rifaximin; TMPSMX: Trimethoprim-sulfamethoxazole; SUCRA: Surface under the cumulative ranking.

Figure 3 Network meta-analysis of studies assessing the risk of death/transplant. A: Network of treatment comparisons between antibiotics. Numbers indicate the number of studies comparing the two connected treatment arms; B: Relative effects of between each treatment. The numbers in the cell represent the odds ratio (95%CI) of the column defining modality relative to the row defining treatment; C: Rank probability (consistency model) for each antibiotic. Indicated is the possibility of each rank (No. 5 is the best). The overall rank interpreted by surface under the cumulative ranking technique is shown in the table. surface under the cumulative rankings in the table are reordered in the conventional ascending sequence. CPFX: Ciprofloxacin; NFX: Norfloxacin; RFX: Rifaximin; TMPSMX: Trimethoprim-sulfamethoxazole; SUCRA: Surface under the cumulative ranking.